Clinical Trials Browser

Interventional × Disease × daratumumab × Clear all

NCT03896737 2025-08-11

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Phase 2 Active not recruiting

Disease, Multiple Myeloma

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Phase 1 Terminated

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence